Amgen Inc AMGN
We take great care to ensure that the data presented and summarized in this overview for AMGEN INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AMGN
View all-
Vanguard Group Inc Valley Forge, PA52.7MShares$16.2 Billion0.25% of portfolio
-
Black Rock Inc. New York, NY46MShares$14.2 Billion0.33% of portfolio
-
State Street Corp Boston, MA29.4MShares$9.07 Billion0.31% of portfolio
-
Morgan Stanley New York, NY14.6MShares$4.49 Billion0.27% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA13.2MShares$4.07 Billion0.65% of portfolio
-
Primecap Management CO Pasadena, CA13MShares$4.01 Billion2.68% of portfolio
-
Geode Capital Management, LLC Boston, MA12.5MShares$3.84 Billion0.26% of portfolio
-
Capital International Investors Los Angeles, CA12.2MShares$3.76 Billion0.62% of portfolio
-
Wells Fargo & Company San Francisco, CA7.13MShares$2.2 Billion0.43% of portfolio
-
Capital World Investors Los Angeles, CA6.5MShares$2 Billion0.27% of portfolio
Latest Institutional Activity in AMGN
Top Purchases
Top Sells
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Insider Transactions at AMGN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 21
2025
|
David M Reese EVP & Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
25,225
-40.59%
|
$7,668,400
$304.44 P/Share
|
Feb 19
2025
|
David M Reese EVP & Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
8,711
-12.29%
|
$2,552,323
$293.22 P/Share
|
Feb 19
2025
|
David M Reese EVP & Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,711
+10.95%
|
$1,358,916
$156.35 P/Share
|
Feb 19
2025
|
Esteban Santos EVP, Operations |
SELL
Open market or private sale
|
Direct |
8,711
-10.85%
|
$2,543,612
$292.84 P/Share
|
Feb 19
2025
|
Esteban Santos EVP, Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
8,711
+9.79%
|
$1,358,916
$156.35 P/Share
|
Feb 19
2025
|
Derek Miller SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
1,524
-15.14%
|
$446,532
$293.74 P/Share
|
Feb 19
2025
|
Derek Miller SVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
1,524
+13.15%
|
$237,744
$156.35 P/Share
|
Feb 18
2025
|
Derek Miller SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
500
-5.53%
|
$146,000
$292.56 P/Share
|
Feb 11
2025
|
Murdo Gordon EVP, Global Commercial Ops |
SELL
Open market or private sale
|
Direct |
8,771
-16.56%
|
$2,578,674
$294.79 P/Share
|
Feb 07
2025
|
Jonathan P Graham EVP & Gen. Counsel & Secy. |
SELL
Open market or private sale
|
Direct |
25,045
-46.35%
|
$7,338,185
$293.12 P/Share
|
Feb 07
2025
|
Jonathan P Graham EVP & Gen. Counsel & Secy. |
BUY
Exercise of conversion of derivative security
|
Direct |
25,045
+31.67%
|
$3,907,020
$156.35 P/Share
|
Feb 05
2025
|
Nancy A. Grygiel SVP & CCO |
SELL
Open market or private sale
|
Direct |
1,589
-18.06%
|
$483,056
$304.47 P/Share
|
Dec 05
2024
|
Jonathan P Graham EVP & Gen. Counsel & Secy. |
SELL
Bona fide gift
|
Direct |
6,430
-18.2%
|
-
|
Dec 02
2024
|
Robert A Bradway Chairman, CEO and President |
SELL
Bona fide gift
|
Direct |
186,000
-16.47%
|
-
|
Dec 02
2024
|
Robert A Bradway Chairman, CEO and President |
BUY
Bona fide gift
|
Indirect |
90,000
+50.0%
|
-
|
Nov 05
2024
|
Matthew C. Busch VP, Finance & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
189
-3.81%
|
$59,724
$316.91 P/Share
|
Nov 05
2024
|
Rachna Khosla SVP, Business Development |
SELL
Payment of exercise price or tax liability
|
Direct |
212
-2.47%
|
$66,992
$316.91 P/Share
|
Nov 04
2024
|
Omar Ishrak Director |
BUY
Grant, award, or other acquisition
|
Direct |
220
+4.15%
|
-
|
Nov 04
2024
|
Michael V Drake Director |
BUY
Grant, award, or other acquisition
|
Direct |
220
+5.83%
|
-
|
Nov 04
2024
|
Charles M Holley Director |
BUY
Grant, award, or other acquisition
|
Direct |
268
+2.58%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 148K shares |
---|---|
Exercise of conversion of derivative security | 44K shares |
Bona fide gift | 90K shares |
Payment of exercise price or tax liability | 71.7K shares |
---|---|
Open market or private sale | 82.2K shares |
Bona fide gift | 192K shares |